LIGAND PHARMACEUTICALS INC
10-Q, EX-27.1, 2000-11-14
PHARMACEUTICAL PREPARATIONS
Previous: LIGAND PHARMACEUTICALS INC, 10-Q, 2000-11-14
Next: E DIGITAL CORP, 10QSB, 2000-11-14



<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from SEC Form
10-Q for the three months ended September 30, 2000 and is qualified in its
entirety by reference to such financial statements. (In thousands except
earnings per share.)

</LEGEND>

<S>                                            <C>
<PERIOD-TYPE>                                  9-MOS
<FISCAL-YEAR-END>                              DEC-31-2000
<PERIOD-START>                                 JAN-01-2000
<PERIOD-END>                                   SEP-30-2000
<CASH>                                         11,969
<SECURITIES>                                   21,027<F4>
<RECEIVABLES>                                  3,685
<ALLOWANCES>                                   (636)
<INVENTORY>                                    6,245
<CURRENT-ASSETS>                               44,036
<PP&E>                                         37,211
<DEPRECIATION>                                 25,427
<TOTAL-ASSETS>                                 115,011
<CURRENT-LIABILITIES>                          22,455
<BONDS>                                        122,896<F1>
                          0
                                    0
<COMMON>                                       56
<OTHER-SE>                                     (30,396)<F2>
<TOTAL-LIABILITY-AND-EQUITY>                   115,011
<SALES>                                        6,477
<TOTAL-REVENUES>                               12,070
<CGS>                                          2,238
<TOTAL-COSTS>                                  2,238<F3>
<OTHER-EXPENSES>                               13,229
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             3,221
<INCOME-PRETAX>                                (14,926)
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            (14,926)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (14,926)
<EPS-BASIC>                                    (0.26)
<EPS-DILUTED>                                  (0.26)


<FN>
<F1>
INCLUDES CONVERTIBLE NOTES AND DEBENTURES, LONG-TERM PORTION OF EQUIPMENT
FINANCING ARRANGEMENTS, AND ACCRUED ACQUISITION OBLIGATION.

<F2>
INCLUDES ADDITIONAL PAID IN CAPITAL, OTHER ADDITIONAL CAPITAL AND RETAINED
EARNINGS, APPROPRIATED AND UNAPPROPRIATED.

<F3>
PER CHIEF ACCOUNTANT AT THE SEC, THIS AMOUNT EXCLUDES SALES AND G&A EXPENSES,
INCLUDES COSTS AND EXPENSES APPLICABLE TO SALES AND REVENUES, AND TANGIBLE COSTS
OF GOODS SOLD.

<F4>
INCLUDES SHORT-TERM INVESTMENTS AND RESTRICTED INVESTMENTS.
</FN>

</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission